SCHEMBL3573365

SCHEMBL3573365

CCOC(=O)c1c(C)nsc1NC1CC1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.44
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 6/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 4/20 0.41
MAPK1 P28482 3/20 0.41
HPGD P15428 3/20 0.41
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957824 0.80 PDE4D (0.47) PDE4DRAB9AALDH1A1MAPTMAPK1
SCHEMBL3584391 0.80 ALDH1A1 (0.37) ALDH1A1L3MBTL1KDM4E
SCHEMBL29295146 0.78 MAPK1 (0.62) PDE4DRAB9AALDH1A1MAPTMAPK1
SCHEMBL9957767 0.78 PDE4D (0.45) PDE4DRAB9AALDH1A1L3MBTL1MAPT
SCHEMBL11405426 0.77 RAB9A (0.48) PDE4DRAB9AALDH1A1MAPTMAPK1
SCHEMBL7372633 0.73 ALDH1A1 (0.47) RAB9AALDH1A1MAPTMAPK1HPGD
SCHEMBL1527760 0.73 PDE4D (0.53) PDE4DRAB9AALDH1A1L3MBTL1MAPT
SCHEMBL10488619 0.72 PDE4D (0.58) PDE4DMAPTHPGDKDM4ETSHR
SCHEMBL1527674 0.71 ALDH1A1 (0.59) PDE4DRAB9AALDH1A1MAPTMAPK1
SCHEMBL22230710 0.71 PDE4D (0.51) PDE4DRAB9AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC PDE4D 3019/4885RAB9A 1226/4885ALDH1A1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.